Genetic Variants in the Cytochrome P450 2D6 Gene in the Sri Lankan Population

Overview

Journal Indian J Hum Genet

Specialty Genetics

Date 2014 Feb 6

PMID 24497701

Citations 3

Authors

T D Praveen Tharanga

C M V Jinadasa

M F Risama

Priyadarshani Galappatthy

R L Jayakody

Vajira H W Dissanayake

Affiliations

Soon will be listed here.

Abstract

Introduction: Cytochrome P450 2D6 (CYP2D6) enzymes are involved in the metabolism of a large number of commonly prescribed drugs such as antidepressants and cardiovascular drugs. The CYP2D6 *3, *4 and *14 variants associated with the loss of enzyme function; CYP2D6 *10 and *17 variants with reduced enzyme function; and CYP2D6 *2 variant with no effect on enzyme function. Establishing the frequency of these variant alleles in Sri Lankan population would be useful for optimizing pharmacotherapy with CYP2D6-substrate drugs.

Objective: The objective of this study was to determine the prevalence of CYP2D6 *2, *3, *4, *10, *14 and *17 variants in the main ethnic groups in the Sri Lankan population.

Materials And Methods: A total of 90 deoxyribonucleic acid (DNA) samples (30 each from Sinhalese, Tamils and Moors) were selected from a DNA resource at the Human Genetic Unit, Faculty of Medicine, University of Colombo. This collection had been made for population genetic studies from a random population based volunteers. Genotyping was performed using published polymerase chain reaction/restriction fragment length polymorphism methods.

Results: The prevalence of the CYP2D6 variants in Sinhalese, Sri Lankan Tamils and Moors respectively were CYP2D6 *2: 37%, 41.6% and 37.9%; CYP2D6 *3: 60.3%, 45% and 30%; CYP2D6 *4: 21.6%, 6.6% and 8.3%; CYP2D6 *10: 40%, 35% and 44%. CYP2D6 *14 and *17 variants were not identified.

Conclusion: CYP2D6*3, *4 and *10 variants, which are associated with reduced or loss of CYP2D6 enzyme function were found in our population in significant frequencies. CYP2D6*4, which is reported to be a Caucasian variant was also found in all three ethnic groups.

Citing Articles

Pharmacogenomic profiling of variants affecting efficacy and toxicity of anti-infective medicines in a south Asian population from Sri Lanka.

Ranasinghe P, Jeyapragasam H, Sirisena N, Hendalage D, Dissanayake V BMC Infect Dis. 2025; 25(1):153.

PMID: 39893405 PMC: 11786550. DOI: 10.1186/s12879-025-10538-w.

Design and implementation of a novel pharmacogenetic assay for the identification of the CYP2D6*10 genetic variant.

Ranadeva N, Sirisena N, Wetthasinghe T, Noordeen N, Dissanayake V BMC Res Notes. 2022; 15(1):104.

PMID: 35296326 PMC: 8925205. DOI: 10.1186/s13104-022-05993-6.

Genetics and genomic medicine in Sri Lanka.

Sirisena N, Dissanayake V Mol Genet Genomic Med. 2019; 7(6):e744.

PMID: 31106988 PMC: 6565544. DOI: 10.1002/mgg3.744.

polymorphisms may predict occurrence of adverse effects to tamoxifen: a preliminary retrospective study.

Wickramage I, Tennekoon K, Ariyaratne M, Hewage A, Sundralingam T Breast Cancer (Dove Med Press). 2017; 9:111-120.

PMID: 28293118 PMC: 5345689. DOI: 10.2147/BCTT.S126557.

References

McLellan R, Oscarson M, Seidegard J, Evans D, Ingelman-Sundberg M . Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics. 1997; 7(3):187-91. DOI: 10.1097/00008571-199706000-00003. View

Weerasuriya K, Jayakody R, Smith C, Wolf C, Tucker G, Lennard M . Debrisoquine and mephenytoin oxidation in Sinhalese: a population study. Br J Clin Pharmacol. 1994; 38(5):466-70. PMC: 1364882. DOI: 10.1111/j.1365-2125.1994.tb04384.x. View

Masimirembwa C, Persson I, Bertilsson L, Hasler J, Ingelman-Sundberg M . A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. Br J Clin Pharmacol. 1996; 42(6):713-9. PMC: 2042718. DOI: 10.1046/j.1365-2125.1996.00489.x. View

Islam S, Idle J, Smith R . The polymorphic 4-hydroxylation of debrisoquine in a Saudi arab population. Xenobiotica. 1980; 10(11):819-25. DOI: 10.3109/00498258009033812. View

Zhou S . Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet. 2009; 48(11):689-723. DOI: 10.2165/11318030-000000000-00000. View

Ingelman-Sundberg M . Duplication, multiduplication, and amplification of genes encoding drug-metabolizing enzymes: evolutionary, toxicological, and clinical pharmacological aspects. Drug Metab Rev. 1999; 31(2):449-59. DOI: 10.1081/dmr-100101930. View

Doshi B, Kulkarni R, Chauhan B, Wilkinson G . Frequency of impaired mephenytoin 4'-hydroxylation in an Indian population. Br J Clin Pharmacol. 1990; 30(5):779-80. PMC: 1368181. DOI: 10.1111/j.1365-2125.1990.tb03850.x. View

Saha N . Blood genetic markers in Sri Lankan populations--reappraisal of the legend of Prince Vijaya. Am J Phys Anthropol. 1988; 76(2):217-25. DOI: 10.1002/ajpa.1330760210. View

Lamba V, Lamba J, Dilawari J, Kohli K . Genetic polymorphism of CYP2D6 in North Indian subjects. Eur J Clin Pharmacol. 1999; 54(9-10):787-91. DOI: 10.1007/s002280050552. View

10.

Marez D, Legrand M, Sabbagh N, Lo Guidice J, Spire C, Lafitte J . Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics. 1997; 7(3):193-202. DOI: 10.1097/00008571-199706000-00004. View

11.

Kirchheiner J, Brosen K, Dahl M, Gram L, Kasper S, Roots I . CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand. 2001; 104(3):173-92. DOI: 10.1034/j.1600-0447.2001.00299.x. View

12.

Griese E, Ofori-Adjei D, Mikus G, Eichelbaum M . Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population. Pharmacogenetics. 2000; 9(6):715-23. View

13.

Garcia-Barcelo M, Chow L, Chiu H, Wing Y, Lee D, Lam K . Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population. Clin Chem. 2000; 46(1):18-23. View

14.

Tateishi T, Chida M, Ariyoshi N, Mizorogi Y, Kamataki T, Kobayashi S . Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population. Clin Pharmacol Ther. 1999; 65(5):570-5. DOI: 10.1016/S0009-9236(99)70077-9. View

15.

Griese E, Ilett K, Kitteringham N, Eichelbaum M, Powell H, Spargo R . Allele and genotype frequencies of polymorphic cytochromes P4502D6, 2C19 and 2E1 in aborigines from western Australia. Pharmacogenetics. 2001; 11(1):69-76. DOI: 10.1097/00008571-200102000-00008. View

16.

Naveen A, Adithan C, Soya S, Gerard N, Krishnamoorthy R . CYP2D6 genetic polymorphism in South Indian populations. Biol Pharm Bull. 2006; 29(8):1655-8. DOI: 10.1248/bpb.29.1655. View

17.

Gaedigk A, Bradford L, Marcucci K, Leeder J . Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clin Pharmacol Ther. 2002; 72(1):76-89. DOI: 10.1067/mcp.2002.125783. View

18.

Kubota T, Yamaura Y, Ohkawa N, Hara H, Chiba K . Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br J Clin Pharmacol. 2000; 50(1):31-4. PMC: 2014971. DOI: 10.1046/j.1365-2125.2000.00209.x. View